India, Aug. 13 -- It has been a banner year so far for Cullinan Therapeutics Inc. (CGEM), with multiple positive clinical readouts across its pipeline fueling share price momentum.
This clinical-stage biopharmaceutical company is developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Its pipeline includes Zipalertinib, CLN-049, CLN-978 and Velinotamig.
When did we first highlight CGEM?
Cullinan Therapeutics was first featured on our site on June 29, 2025, when its shares were trading at $7.93. Our report highlighted the key catalyst events to watch, with a focus on Zipalertinib.
Originally discovered by Japan-based Taiho Pharmaceutical, Zipalertinib was licensed to Cullinan Th...